𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Symposium S02: Progress on the pathogenesis of hereditary neurodegenerative disorders

✍ Scribed by L. Notterpek


Book ID
111195906
Publisher
John Wiley and Sons
Year
2005
Tongue
English
Weight
339 KB
Volume
94
Category
Article
ISSN
0022-3042

No coin nor oath required. For personal study only.


πŸ“œ SIMILAR VOLUMES


Thirteenth annual symposium on etiology,
πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 English βš– 85 KB πŸ‘ 2 views

The morning session will focus on the Etiology, Pathogenesis, and Treatment of Parkinson's Disease. It consists of a keynote speaker and 10 presentations by the following individuals with allotted time for questions and answers after each presenter.

Twenty second annual symposium on etiolo
πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 127 KB πŸ‘ 1 views

## Abstract This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through joint sponsorship of The Movement Disorder Society and The Parkinson Study Group. The Movement Disorder Societ

Program: Twenty Third Annual Symposium o
πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 132 KB πŸ‘ 1 views

## Abstract The symposium will consist of two keynote speakers and peer‐reviewed platform and poster presentations designed to communicate recent research advances, including new pharmacological and non‐pharmacological treatment options, in the field of Parkinson's disease, Huntington disease, atax

Program: Twenty Fourth Annual Symposium
✍ Presented by the Parkinson Study Group; Huntington Study Group; Dystonia Study G πŸ“‚ Article πŸ“… 2010 πŸ› John Wiley and Sons 🌐 English βš– 129 KB πŸ‘ 1 views

## Abstract The symposium will consist of current issues in genetic and environmental contributions to Parkinson's disease and other movement disorders with peer‐reviewed platform and poster presentations designed to communicate recent research advances, including new pharmacological and non‐pharma